RE: Reporting Standards7 May 2021 09:01
C11,
Here are the AIM rules on disclosure:
"An AIM company must issue notification without delay of any new developments which are not public knowledge concerning a change in:
its financial condition;
its sphere of activity;
the performance of its business; or
its expectation of its performance,
which, if made public, would be likely to lead to a substantial movement in the price of its AIM securities."
So any progress on the clinical front would certainly come under "sphere of activity". If a patient had been dosed (or even recruited!), news of this WOULD have a substantial effect on the share price so would have to be reported (IMO).
So whilst lack of news may suggest no significant milestones such as patient dosed, that's not to say progress isn't being made. I fully believe it is.